Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Xilio Therapeutics, Inc.
Report date October 26, 2021 · Filed November 03, 2021 · Amendment
Jointly reported with SV7 Impact Medicine Fund LP
Section 16 reporting ended · disclosed 2021-11-03. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 998,544 |
Reported balance
After 2021-10-26 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-10-26 · Conversion · Acquired 998,544 · Balance 998,544 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. |
| Common StockSEC Table I · non-derivative | Direct | 1,301,132 |
Reported balance
After 2021-10-26 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2021-10-26 · Conversion · Acquired 302,588 · Balance 1,301,132 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. |
| Common StockSEC Table I · non-derivative | Direct | 1,613,632 |
Reported balance
After 2021-10-26 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2021-10-26 · Purchase · Acquired 312,500 · Balance 1,613,632 F4: This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 998,544 |
Reported balance
After 2021-10-26 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2021-10-26 · Conversion · Acquired 998,544 · Balance 998,544 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,301,132 |
Reported balance
After 2021-10-26 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2021-10-26 · Conversion · Acquired 302,588 · Balance 1,301,132 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,613,632 |
Reported balance
After 2021-10-26 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2021-10-26 · Purchase · Acquired 312,500 · Balance 1,613,632 F4: This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-26 transaction · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · 2021-10-26 · Conversion · Disposed 9,486,166 · Balance 0 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-10-26 transaction · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · 2021-10-26 · Conversion · Disposed 9,486,166 · Balance 0 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-26 transaction · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · 2021-10-26 · Conversion · Disposed 2,874,595 · Balance 0 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-10-26 transaction · row 10
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 10 · 2021-10-26 · Conversion · Disposed 2,874,595 · Balance 0 F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
F2: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
F3: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
F4: This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,874,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · derivative · entry 8 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 302,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,874,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · derivative · entry 7 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 302,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries B Convertible Preferred Stock · Derivative | 9,486,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · derivative · entry 6 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 998,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries B Convertible Preferred Stock · Derivative | 9,486,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · derivative · entry 5 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 998,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 302,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · nonDerivative · entry 4 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,301,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 302,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · nonDerivative · entry 3 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 998,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · nonDerivative · entry 2 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 998,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 12:55 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 998,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-041838 · doc4.xml · nonDerivative · entry 1 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,874,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · derivative · entry 10 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 302,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,874,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · derivative · entry 9 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 302,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries B Convertible Preferred Stock · Derivative | 9,486,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · derivative · entry 8 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 998,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries B Convertible Preferred Stock · Derivative | 9,486,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · derivative · entry 7 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 998,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | PurchaseCommon Stock | 312,500 | $16.00 | $5,000,000.00 |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · nonDerivative · entry 6 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,613,632 F4 · shares: This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | PurchaseCommon Stock | 312,500 | $16.00 | $5,000,000.00 |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · nonDerivative · entry 5 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,613,632 F4 · shares: This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 302,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · nonDerivative · entry 4 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,301,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 302,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · nonDerivative · entry 3 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 998,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · nonDerivative · entry 2 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 998,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. F3 · ownership.nature: Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Read SEC document |
| October 26, 2021 Filed Nov 3, 2021 16:20 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 998,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042710 · doc4a.xml · nonDerivative · entry 1 SV7 Impact Medicine Fund LP · CIK 0001780602 · 10% owner SV7 (IMF) GP LLP · CIK 0001889859 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. F2 · balance_after: Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.